Amryt Pharma PLC Attendance at Rodman & Renshaw Conference
August 31 2017 - 1:01AM
RNS Non-Regulatory
TIDMAMYT
Amryt Pharma PLC
31 August 2017
31 August 2017
AIM: AMYT
ESM: AYP
Amryt Pharma plc
("Amryt" or the "Company")
Amryt to Present at the Rodman & Renshaw Annual Healthcare
Conference
Amryt Pharma, a biopharmaceutical company focused on
best-in-class treatments for rare and orphan diseases, announces
that Rory Nealon, Chief Financial Officer, will present a corporate
overview at the upcoming Rodman & Renshaw Annual Healthcare
Conference on Tuesday, September 12, 2017 at 1:45 p.m. ET in New
York.
A live webcast of the presentation will be available in the
Investors & Media section of the Company's website at
www.amrytpharma.com.
Enquiries:
Amryt Pharma plc C/o KTZ Communications
Joe Wiley, CEO
Rory Nealon, CFO/COO
+44 (0) 20 3178
KTZ Communications 6378
Katie Tzouliadis, Irene
Bermont-Penn
Emma Pearson
About Amryt Pharma plc
(www.amrytpharma.com)
Amryt Pharma is a specialty pharmaceutical company focused on
developing and delivering innovative new treatments to help improve
the lives of patients with rare or orphan diseases. The Company is
building a diversified portfolio of commercially attractive,
best-in-class, proprietary new drugs to help address some of these
rare and debilitating illnesses for which there are currently no
available treatments.
The Company holds an exclusive licence to sell Lojuxta
(lomitapide) for adults, across the EU and other territories
including the Middle East, North Africa, Turkey and Israel. Lojuxta
is used to treat a rare life-threatening disease called Homozygous
Familial Hypercholesterolemia, which impairs the body's ability to
remove LDL cholesterol ("bad" cholesterol) from the blood. This
typically results in extremely high blood LDL cholesterol levels
leading to aggressive and premature narrowing and blocking of
arterial blood vessels. If left untreated, heart attack or sudden
death may occur in childhood or early adulthood.
Amryt's lead drug candidate, AP101 (Episalvan), is a potential
treatment for Epidermolysis Bullosa ("EB"), a rare and distressing
genetic skin disorder affecting young children for which there is
currently no treatment. It is currently in Phase 3 clinical trials.
The global market opportunity for EB is estimated to be in excess
of EUR 1.3 billion.
Amryt's earlier stage product AP102 is focused on developing
novel, next generation somatostatin analogue ("SSA") peptide
medicines for patients with rare neuroendocrine diseases, where
there is a high unmet medical need, including acromegaly and
Cushing's disease.
The Company joined AIM and Dublin's ESM in April 2016 following
the reverse takeover of Fastnet Equity PLC.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRADMGFRDGNGNZM
(END) Dow Jones Newswires
August 31, 2017 02:01 ET (06:01 GMT)
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From Apr 2024 to May 2024
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From May 2023 to May 2024